The analyst thinks ZBH’s 3Q sales miss was disappointing but considering the 14% pullback, with ZBH back at a ~6x P/E discount to the large cap MedTech avg., the valuation appears to be disconnected from the company’s double digit EPS growth prospects and longer-term mid single digit top-line potential.

For an analyst ratings summary and ratings history on Zimmer Biomet click here. For more ratings news on Zimmer Biomet click here.